Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Sort descending Date Submission Received Date Recommendation Issued
Cosentyx Secukinumab Plaque psoriasis List with criteria/condition Complete
Dymista Azelastine HCl and fluticasone propionate Seasonal allergic rhinitis Do not list Complete
Spiriva Respimat Tiotropium bromide Chronic obstructive pulmonary disease List with clinical criteria and/or conditions Complete
Incruse Ellipta Umeclidinium Chronic obstructive pulmonary disease List with criteria/condition Complete
Sunvepra Asunaprevir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete
Daklinza Daclatasvir Hepatitis C, Chronic List with clinical criteria and/or conditions Complete
Entyvio Vedolizumab Ulcerative colitis List with clinical criteria and/or conditions Complete
Prolia Denosumab (Drug Plan Submission) Osteoporosis, men List with clinical criteria and/or conditions Complete
Brenzys Etanercept Rheumatoid arthritis, Ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete
Inflectra (Subsequent Entry Biologic) Infliximab Crohn’s disease and Ulcerative Colitis Reimburse with clinical criteria and/or conditions Complete